CEO ROUNDTABLE ON CANCER

COLLABORATION • INNOVATION • INSPIRATION

Attendee Bios

SAS | CARY, NC
NOVEMBER 13 – 14, 2018

Gale Adcock

Chief Health Officer
SAS

Dawn Aubel, EdD, MPH, APNc

Director of Patient Relations in Global Development, Medical Affairs and Breast Cancer
Novartis Oncology
Co-Chair, *CEO Cancer Gold Standard* Task Force

Dr. Dawn Aubel is Director of Patient Relations in Global Development, Medical Affairs, and Breast Cancer at Novartis Oncology. In her previous role, she was responsible for strategy, design, implementation and evaluation of health and wellness initiatives for the large employee population of Novartis AG.

Dr. Aubel received a doctorate in health services organization and leadership from Teachers College, Columbia University. She also has a master's degree in nursing and a master's degree in public health from Columbia University. Her undergraduate degree in nursing is from Virginia Commonwealth University. She is certified by the American Nurses Certification Center as a Family Nurse Practitioner. Dr. Aubel has extensive experience in primary and survivorship care and in health services delivery. She won the CancerCare of N.J. President's Award for her work in wellness, and the company's Global HR Award for the cancer survivorship initiative.

Roy D. Baynes, MD, PhD

Senior Vice President, Head of Global Clinical Development and Chief Medical Officer
Merck Research Laboratories

Dr. Roy Baynes is Senior Vice President of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, NJ. Previously, Dr. Baynes was Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, and Vice President of Global Clinical Development and Therapeutic Area (TA) Head for Hematology/ Oncology at Amgen Inc. He graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa. He has had a long and distinguished career in the hematology, oncology and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been frequently named among America's top physicians. Before joining Amgen in 2002, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University in Detroit.

Joel W. Beetsch, PhD

Vice President of Global Patient Advocacy, Corporate Affairs
Celgene Corporation

Dr. Joel Beetsch leads the global development and execution of a coordinated patient-focused advocacy strategy at Celgene, working with multiple patient, provider, payer and policy organizations to foster safe and effective solutions to health care challenges. These efforts drive the assurance that patient access to health care solutions and medical innovation are valued and advanced.

During his 20-year tenure in the biopharmaceutical industry, Dr. Beetsch has held several medical and corporate affairs positions. He has professional interests in patient-focused care coordination, health policy and the use of health information technology. Dr. Beetsch is also one of the founding members of *Project Data Sphere*, a data sharing platform on which researchers can share, integrate and analyze patient-level, deidentified, phase III cancer data. He has also served as the chairperson for the steering committee of the Reagan Udall Foundation Big Data for Patients (BD4P) initiative and is extensively engaged with the Clinical Trials Transformation Initiative (CTTI) efforts to connect patients and patient groups to the research and development process.

Dr. Beetsch earned his doctorate in neurobiology/biochemistry from the Boonshoft School of Medicine at Wright State University and further training at the Washington University School of Medicine.

Bret Belfer

Director of Employee Wellness and Recognition
MD Anderson Cancer Center

Josh Bilenker, MD

Founder, President and Chief Executive Officer
Loxo Oncology

In addition to being the founder, President and CEO of Loxo Oncology, Dr. Josh Bilenker also sits on the board of directors.

Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in New York, where he remains an Operating Partner. From 2004 to 2006, Dr. Bilenker worked as a Medical Officer at the US Food and Drug Administration in the Office of Oncology.

Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his MD from the Johns Hopkins School of Medicine and his AB from Princeton University.

Robert A. Bradway

Chairman, *CEO Roundtable on Cancer*
Chairman and Chief Executive Officer, Amgen

Mr. Robert Bradway is Amgen's Chairman and Chief Executive Officer. He became Chairman in January 2013 and Chief Executive Officer in May 2012. Mr. Bradway served as the company's President and Chief Operating Officer from May 2010 to May 2012, and was appointed to the Amgen board of directors in October 2011. He joined the company in 2006 as Vice President of Operations Strategy, and served as Executive Vice President and Chief Financial Officer from April 2007 to May 2010.

Prior to joining Amgen, he was a managing director at Morgan Stanley in London, where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe. Mr. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990.

He is a member of the board of directors of The Boeing Company, serving on its Audit and Finance committees. Mr. Bradway serves on the board of trustees of the University of Southern California and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university.

Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard University.

Riccardo Braglia

Vice Chairman and Chief Executive Officer
Helsinn Group

Mr. Riccardo Braglia is Helsinn Group's Vice Chairman, CEO and Managing Director. He is a member of Helsinn Holding's board of directors, Switzerland, and of the executive committee for Helsinn Group's strategic management. He is a board member of Helsinn Healthcare, Switzerland; Helsinn Advanced Synthesis, Switzerland; and Helsinn Birex Pharmaceuticals, Ireland. He is also Chairman of Helsinn Therapeutics' board of directors, US; Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco; and Chairman of Helsinn Investment Fund, Luxembourg.

Mr. Braglia has over 30 years of international experience in the pharmaceutical industry. He heads the family-run, privately owned pharmaceutical company the Helsinn Group, founded in 1976, which is committed to improving the everyday lives of people with cancer through a focus on oncology therapeutics and supportive care.

Mr. Braglia is a board member of Thorne Research, US, Wellness-Fx, HealthElements.com and Lyfebulb, which he also co-founded. He is active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures.

Mr. Braglia holds a degree in business economics with specialization in industrial management from Luigi Bocconi University, Milan.

Christine Brennan

Director of Programs
Cancer and Careers

Ms. Christine Brennan joined Cancer and Careers in 2014. As Director of Programs, she serves as Copy Chief for CAC's vast array of print and digital publications, oversees the organization's annual National and West Coast Conferences on Work and Cancer, manages CAC's website — from operations to content – and SEO/SEM activities, and delivers presentations to diverse audiences around the country, including patients, survivors, HR professionals and employers. Recent presentations include Living Beyond Breast Cancer's Annual Conference, CHOC Children's Hospital's AYA Career and Resource Expo, American Society for Healthcare Human Resources Administration's Regional Conference and the US Department of Energy's Annual Contractor Employee Assistance Training.

Ms. Brennan brings to the role more than two decades of experience in communications, public relations, marketing and event management, including roles at Health magazine, Self magazine, Lifetime television and the PR/marketing firm Maloney & Fox, part of Waggener Edstrom Communications. In addition, she served as a Health Education Resource Volunteer for the US Peace Corps in Kenya.

Ann Burke

Executive Director for Benefits and Wellness
Boehringer Ingelheim

Ms. Ann Burke is responsible for the strategic design and delivery of the US-based benefits and wellness programs at Boehringer Ingelheim (BI) as well as the multifaceted recognition program. She is a graduate of George Mason University.

Ms. Burke has focused her energy on providing tools and resources for BI employees and family members to live healthy lives. Her approach is to incorporate the physical, emotional and financial aspects of healthy living including a focus on appreciation and employee recognition.

She has introduced the Insure Fit colorectal cancer program through BI's partnership with Aetna and Quest Labs to increase member awareness of colon cancer prevention and provide a simple testing opportunity in the home setting. Since 2015 when the program was initially rolled out, the completion rate by members has increased, and early findings have led to preventive action.

Ms. Burke is dedicated to bringing programs and services to BI that support employees and family members in their quest for good health and outcomes. She also proudly supports Ann's Place, The Home Of I Can, a local organization that provides education and resources to those dealing with a cancer diagnosis as well as their family members.

Bruce Chabner

Clinical Director, Emeritus
Massachusetts General Hospital

John Crumpler

General Partner
Hatteras Venture Partners

Mr. John Crumpler co-founded Hatteras Venture Partners in 2000 after a successful career as a technology entrepreneur. After a decade in politics and public policy, he was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing. Following E-Comm's acquisition by XcelleNet, Inc., Mr. Crumpler ran the services division there until the company was acquired by Sterling Commerce. Following the acquisition, he founded Hatteras with Clay Thorp.

With his partners at Hatteras, Mr. Crumpler has helped build a seed and early stage venture capital partnership with over $450 million in five funds. At Hatteras, he is responsible for the firm's investments in health care and life science information technology, and overall fund operations.

He has served on the boards of Synthematix, a chemistry informatics company that was acquired by Symyx Technologies; Clinverse, a financial life cycle management technology provider to contract research organizations and pharmaceutical companies, acquired by Bioclinica, Inc.; and Bivarus, a survey-based health analytics company acquired by Press Ganey. Mr. Crumpler currently serves on the boards of Elligo Health Research, NurseGrid, Medfusion, Wildflower Health, Jumo Health, and Clinipace Worldwide. He holds an AB from Harvard University.

Louis Denis, MD

Chief Medical Officer
Asana BioSciences LLC

Dr. Louis Denis is the Chief Medical Officer at Asana BioSciences, a biopharmaceutical company based in the Princeton, NJ, area focused on the discovery and development of novel therapeutics for oncology and autoimmune diseases.

Dr. Denis is a medical oncologist with more than 20 years of academic and industry experience in oncology and clinical cancer drug development. He held strategic and leadership positions of increasing responsibility in clinical development and medical affairs at Pfizer and, more recently, at Boehringer Ingelheim. Dr. Denis received his medical degree from the Vrije Universiteit Brussels, Belgium, followed by internal medicine and medical oncology training at Middelheim Hospital, Antwerp; the Rotterdam Cancer Institute, the Netherlands; and the Cancer Therapy and Research Center in San Antonio. He is co-inventor on multiple patents and is co-author of over 40 scientific publications and presentations on cancer clinical research.

Amadou Diarra, PhD

Head of Global Policy, Advocacy and Government Affairs
Bristol-Myers Squibb

Dr. Amadou Diarra leads an integrated organization focused on external environment dynamics, working with key stakeholders including patient support organizations, health care professionals, policymakers and industry associations. He is passionate about partnering for improved health outcomes, saying "In a growingly complex environment, it is clear that no major health care-related challenge can be addressed unilaterally by one stakeholder entity. Cooperation across the health care landscape, building coalitions where appropriate, is of utmost importance if we are to achieve our ultimate ambitions to make a difference for patients and communities."

Dr. Diarra joined Bristol-Myers Squibb in 1991 as Market Research and Business Development Manager, Africa Division. From 1999 to 2002 he led the company's landmark philanthropic program, Secure the Future, a public-private partnership focused on care and support for women and children infected or affected by HIV/AIDS in sub-Saharan Africa. He then spent time as General Manager, Indonesia; General Manager, Turkey; and General Manager for the Ireland and Nordic Region before being promoted to Vice President, Access Europe. In late 2010, he was appointed European Vice President and General Manager, UK and Ireland. During his three-year tenure Dr. Diarra also chaired the European Works Council and sponsored the Cardiovascular and Metabolics Disease Area Committee. As a board member of the Association of the British Pharmaceutical Industry (ABPI), Dr. Diarra chaired the Health Technology Assessment Task Force and the Reputation Strategy Group. He also represented ABPI on the All Wales Medicine Strategy Group.

Prior to joining Bristol-Myers Squibb, Dr. Diarra was the international market research manager at Laboratoire Fournier, Dijon. He holds a doctorate from the School of Pharmacy at the University of Tours, France and a MBA from the École Supérieure de Commerce de Tours. He also completed the General Management Program delivered by the European Center for Executives Development in collaboration with INSEAD.

Dr. Diarra represents Bristol-Myers Squibb as Chair of the Pharmaceutical Research and Manufacturers of America International Section Executive Committee and as a council member of the International Federation of Pharmaceutical Manufacturers and Associations. Dr. Diarra is also a member of Bristol-Myers Squibb's Global Leadership Team, Global Diversity & Inclusion Council and Sustainability Council.

Thomas J. Donohue

President and Chief Executive Officer
US Chamber of Commerce



Since assuming his position at the US Chamber of Commerce in 1997, Mr. Thomas Donohue has built the Chamber into a lobbying and political powerhouse with expanded influence across the globe.

During his tenure, the Chamber has helped secure business victories on Capitol Hill, in the regulatory agencies, politics, courts of law and the court of public opinion, and before governments around the world.

In an era of economic and fiscal challenges, Mr. Donohue has advanced the American Jobs, Growth, and Opportunity Agenda, a plan that includes expanding trade and domestic energy production, rebuilding America's infrastructure, combating new regulations, protecting intellectual property, revitalizing capital markets, and reforming entitlements and the tax system.

Under Mr. Donohue's leadership, the Chamber has emerged as a major political force in races for the Senate and the House of Representatives. As part of this bipartisan effort, millions of grassroots business advocates, as well as the Chamber's federation of state and local chambers and industry associations, mobilize in support of pro-business candidates.

Mr. Donohue established the US Chamber Institute for Legal Reform, which advances significant legal reforms in the courts, at the state and federal levels, and in elections for state attorneys general and Supreme Court judges. He has dramatically expanded the activities of the US Chamber Litigation Center, the Chamber's law firm. And he has reinvigorated the US Chamber of Commerce Foundation, which houses Hiring Our Heroes, a program that identifies job opportunities for tens of thousands of returning veterans and military spouses.

Previously, Mr. Donohue served as President and CEO of the American Trucking Associations, Deputy Assistant Postmaster General of the US and Vice President of Development at Fairfield University in Connecticut.

Mr. Donohue earned a bachelor's degree from St. John's University and a MBA from Adelphi University. He holds honorary degrees from Adelphi, St. John's, Marymount and Bradley universities, as well as the National University of Ireland at Maynooth. He is a 2013 recipient of the Horatio Alger Award.

Dana Dornsife

Chairman of the Board and Founder
Lazarex Cancer Foundation

Mrs. Dana Dornsife founded the national public nonprofit organization Lazarex Cancer Foundation in 2006 to improve the outcome of cancer care for patients from all sectors of our population, in particular the medically underserved. By providing assistance with ancillary costs for FDA clinical trial participation beyond those covered by drug sponsors and insurance, and identifying clinical trial options, Lazarex is removing barriers to cancer clinical trials for all patients – a lifeline for those for whom standard of care has failed. Lazarex is closing the access and survival gap by fostering consistent and culturally appropriate community outreach and engagement, addressing the full continuum of cancer care from prevention through treatment and clinical trial participation.

Mrs. Dornsife has recently expanded the mission at Lazarex to transform the bench to bedside process of clinical trial enrollment, retention and minority participation with IMPACT (IMproving Patient Access to Cancer Clinical Trials), an institutional-level program aimed at creating a sustainable platform of equitable access to cancer trials. She is a graduate of Drexel University in Philadelphia and launched several businesses prior to migrating to the nonprofit sector.

Joaquin Duato

Board Member, *CEO Roundtable on Cancer*
Vice Chairman of the Executive Committee, Johnson & Johnson

Mr. Joaquin Duato is a values-driven health care business leader who has worked in three countries and two regions over his career. He is the Chairman-Elect of the Pharmaceutical Research and Manufacturers of America (PhRMA) and a Board member of Save the Children.

Mr. Duato played an instrumental role in leading the turnaround of the Johnson & Johnson pharmaceuticals business. With a focus on creating innovative solutions and processes, he inspires employees to focus on transforming the lives of patients. With 16 new products launched since 2009 and 10 potential billion-dollar medicines expected to be filed before 2019, the Johnson & Johnson pharmaceuticals sector is poised to remain one of the fastest-growing pharmaceutical companies globally.

A dual citizen of Spain and the US, Mr. Duato appreciates the value of diversity of perspectives. He is a Board member of the US Spain Council, the Executive Sponsor of the African American Leadership Council, and was recognized in 2015 as one of America's Top 10 Hispanic Business Leaders by *Hispanic Career World*.

Ron Z. Goetzel, PhD

Senior Scientist and Director of the Institute for Health and Productivity Studies (IHPS),
Johns Hopkins Bloomberg School of Public Health
Vice President of Consulting and Applied Research, IBM Watson Health

Dr. Ron Goetzel is responsible for leading innovative projects for health care purchaser, managed care, government and pharmaceutical clients interested in conducting cutting-edge research focused on the relationship between health and well-being, medical costs and work-related productivity at the IHPS. He is an expert in health and productivity management, return on investment, program evaluation and outcomes research. Before moving to Johns Hopkins University, Dr. Goetzel was on the faculty at Emory and Cornell universities.

Dr. Goetzel is the principal investigator (PI) for a Robert Wood Johnson Foundation study examining the relationship between an organization's culture of health, employees' health risks, medical costs and company stock price. He served as PI on a five-year project sponsored by the National Heart, Lung and Blood Institute focused on obesity prevention at the workplace. He has also served as PI on projects for the Centers for Medicare and Medicaid Services, the Federal Employee Worksite Health and Wellness Initiative administered by the Office of Personnel Management, and the Centers for Disease Control and Prevention (CDC). He is now a PI on two CDC initiatives focused on updating the CDC Worksite Health ScoreCard and building a comprehensive CDC Workplace Health Resource Center.

In the private sector, Dr. Goetzel has led multiple evaluations of health promotion and disease prevention programs at companies including Boeing, Chevron, General Electric, Dow Chemical, Citibank, Johnson & Johnson, IBM, Procter & Gamble, Duke University, University of Michigan, Vanderbilt University, Motorola, Novartis and PepsiCo. Public sector partners have included King County, Washington; Cayuga County, New York; and the State of Delaware. Health plan and insurance company collaborators include Blue Cross Blue Shield Federal Employee Program, Health Care Services Corporation, Highmark, American Specialty Health, Blue Cross Blue Shield Association, Mayo Clinic and Kaiser Permanente. Dr. Goetzel has also done extensive work with nonprofits including the Robert Wood Johnson Foundation, Health Enhancement Research Organization (HERO), Transamerica Center for Health Studies, American Heart Association and The Health Project. Dr. Goetzel's international work includes projects with Discovery Health in South Africa, the Ministry of Health in Israel, Social Service of Industry in Brazil, and the Health Promotion Board of Singapore.

Dr. Goetzel is a Task Force Member for the Guide to Community Preventive Services (Community Guide) housed at the CDC, and President and CEO of The Health Project, which annually awards the prestigious C. Everett Koop Award to organizations with demonstrable health improvement and cost savings data. He is the Chairperson for HERO and Vice-Chair for the Fries Foundation, housed at the CDC Foundation.

Before joining Truven Health Analytics (now part of IBM Watson Health), Dr. Goetzel was Vice President of Assessment, Data Analysis and Evaluation Services at Johnson & Johnson. He was one of the original members of the core development and marketing group at Corporate Health Strategies. He has published over 200 peer-reviewed articles and book chapters and frequently presents at international business and scientific forums.

Cathryn E. Gunther

Vice President, Global Population Health
Merck

Mrs. Cathryn Gunther is a health care strategist, innovator and collaborator, working across public and private sectors. She specializes in developing strategies and delivering transformational collaborations that create greater health impact for patients, health care consumers and populations in need. Recently, Mrs. Gunther launched MSD's Global Population Health, establishing the corporate framework for innovative population health approaches that create sustained social and business value. She leads the company's workforce well-being strategy, and supports a number of population health advancements in infectious diseases and antimicrobial stewardship, prevention through immunization, women's health and non-communicable diseases. This work also includes advancing the company's thought leadership to improve patient and community health literacy.

She serves on the National Business Group on Health's Well-Being and Workforce Strategy Institute and the Grand View Health Foundation Board, and she is a member of the Global Chief Medical Officers' Network. She serves on the Health Evolution Summit's Leadership Committee and the George Mason University Center for the Advancement of Well-Being.

Sandeep Gupta, PhD

Founder, President and CEO
Asana BioSciences LLC

Dr. Sandeep Gupta leads Asana BioSciences, a biopharmaceutical company based in the Princeton, NJ, area focused on the discovery and development of novel therapeutics for oncology and autoimmune diseases.

Previously, he was the Senior Vice President of Discovery and Early Development at Endo Pharmaceuticals, and the Head of Drug Discovery and Pharmacology at Forest Laboratories (now Allergan). He played a key role in the development of several blockbuster drugs during his tenures at Endo and Forest. Before Forest Laboratories, Dr. Gupta held academic positions at the University of Pennsylvania and Boston University schools of medicine. He received an MS in pharmaceutical sciences from the Indian Institute of Technology, Banaras Hindu University, India; and a PhD from Northeastern University, Boston. Regarded as an architect of the virtual drug discovery research model, he has pioneered several successful discovery and development collaborations across the globe. He is a co-inventor on multiple patents and has authored over 50 scientific papers, presentations and book chapters. Dr. Gupta is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.

Mimi Hancock, PhD

Honorary Member, *CEO Roundtable on Cancer*
Senior Advisor, Frazier Healthcare Partners
Retired Partner, Spencer Stuart

Dr. Mimi Hancock served as a member of Spencer Stuart's Life Sciences Practice through 2016, working out of the San Francisco office. Her executive search experience included assignments for organizations ranging from emerging life sciences companies to multinational biotechnology, pharmaceutical and medical technology firms. She has executed searches for board members as well as senior executives in general management, R&D, a variety of commercial, finance and business development positions.

Before entering the executive search industry, Dr. Hancock served as Vice President of Operations and co-founder at Avigen, a startup gene therapy company. For two years prior, she was the Director of Cell Biology at Somatix Therapy Corporation, a publicly held company focused on gene therapy. Earlier in her career, Dr. Hancock worked at Triton Biosciences, where she conducted pioneering research on a novel therapeutic approach targeting the Her2 protein in breast and ovarian cancer (Hancock et al.; Cancer Research, 1991). She began her career in health care with Peralta Cancer Research Institute as a staff scientist, and previously served on the board of directors of Bionovo, a public company developing novel therapeutics for breast cancer and women's health.

Dr. Hancock is currently devoting time to serving in various advisory and mentoring roles for board-ready executives, as well as career development for students in STEM programs.

Wei He, PhD

Inventor, Founder and CEO
Zhejiang DTRM Biopharma

Dr. Wei He leads Zhejiang DTRM Biopharma and is the inventor or co-inventor of 40 US patents and three issued patents in China, with pending patents in other countries and areas.

Zhejiang DTRM Biopharma is an American-Chinese joint venture founded in 2011 in China. DTRM Biopharma is a clinical-stage company conducting simultaneous clinical trials in the US and China, with patent-protected, clinically differentiated target therapy and first-in-class oral doublet and triplet therapies. The company has raised $73 million in six years.

Prior to founding DTRM Biopharma, Dr. He spent 20 years with Morningside Venture, Adolor Corporation, Vitae Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, Aventis Pharmaceuticals, and Rhône-Poulenc Rorer Pharmaceuticals. Dr. He has a proven track record in the areas of drug discovery, project management and business development. He has discovered and developed many novel clinical drug candidates for treating cancers, cardiovascular diseases, gastroenterology disorders and diabetes including FDA-approved dual targeting medicine Viberzi (Eluxadoline or JNJ27018966). Dr. He's inventions and licensing have contributed to acquisition deals ranging from $300 million to $1.5 billion (Vitae-Boehringer Ingelheim, Adolor-Cubist, Furiex-Forest Lab/Allergan).

Dr. He has a BS degree in chemistry from Peking University and is a member of the elite Chemistry Graduate Program sponsored by the US and China. He earned a PhD degree in chemistry followed by post-doctoral research at The Ohio State University. He is committed to developing better therapies for cancer patients in part due to his father dying of cancer at the age of 65.

Patrick Homer
Global Life Sciences Principal
SAS

Paul Howard
Senior Advisor, Office of the Commissioner
US Food and Drug Administration

Mr. Paul Howard is a Senior Advisor to the Commissioner of the FDA, where he works on matters relating to regulatory policy, strategic innovation initiatives, and promoting competition to efficiently advance public health and safety.

Mr. Howard has nearly 20 years of public policy experience, and has written and researched extensively on FDA related matters while Director of Health Policy and Senior Fellow at the Manhattan Institute.

Nadeem Ishaque
Chief Innovation Officer
GE Healthcare

Reed Jobs
Director of Health
Emerson Collective

Lori Johnston
Senior Vice President of Human Resources
Amgen

Ray Jordan
Senior Vice President
Amgen

Neal F. Kassell, MD

Chairman
Focused Ultrasound Foundation

Dr. Neal Kassell is the founder and Chairman of the Focused Ultrasound Foundation. He was a Professor of Neurosurgery at the University of Virginia from 1984 until 2016, where he was co-chair of the department until 2006.

Before moving to Charlottesville, Dr. Kassell was on the faculty at the University of Iowa for seven years. He received both his undergraduate and medical education at the University of Pennsylvania, where he completed his MD in 1972. After internship and two years of neurology and neurosurgery residency in Philadelphia, Dr. Kassell completed his neurosurgical training with Dr. Charles Drake at the University of Western Ontario.

In April 2016, Dr. Kassell was appointed by Vice President Joe Biden to the National Cancer Institute's Blue Ribbon Panel for Cancer Moonshot Initiative. Dr. Kassell has served on many standing and ad hoc committees of the National Institutes of Health and in an editorial capacity for a variety of academic journals. He has contributed more than 500 publications and book chapters to the literature. Dr. Kassell is a member of numerous medical societies in the US and abroad.

Dr. Kassell was a founder of Interax Inc., the Virginia Neurological Institute, Multimedia Medical Systems Inc., the Neuroclinical Trials Center, the NeuroVenture Fund, MedSpecialists.net, and the Focused Ultrasound Foundation. He has served on a number of public and private sector boards, including Eclypsis Corporation, INC Research, the Prostate Cancer Foundation, Virginia National Bank, InSightec Inc., The Lagesse Foundation, and Expedition Trust Company. He is a shareholder of Insightec Inc.

Russel Kaufman, MD

Executive-in-Residence and Scientific Advisory Board, Pappas Ventures
President Emeritus, The Wistar Institute

Dr. Russel Kaufman is President Emeritus of The Wistar Institute and previously served as the Director of The Wistar Cancer Center. Prior to his role at The Wistar Institute, he was the Vice Dean and Associate Vice Chancellor at the Duke University School of Medicine, where he is now professor emeritus. He also serves as a Wistar Professor in the Adjunct Faculty at the University of Pennsylvania. Dr. Kaufman's research focuses on genetics, cancer and blood diseases. He is certified in internal medicine and has practiced hematology and medical oncology. He has held leadership positions in national academic organizations in internal medicine and on committees within the NIH, the National Academy of Sciences, the American Cancer Society and the American Association of Medical Colleges. He serves on the boards of the University City Science Center, Osage Ventures, Biorasi and BioAdvance. He is a consultant to Kentmere Healthcare and CEO of Kaufman LifeSciences, LLC.

Dr. Kaufman joined Pappas Ventures in 2008 as a member of the Scientific Advisory Board, becoming an Executive-in-Residence in 2015.

Sean Khozin, MD, MPH

Associate Director, Oncology Center of Excellence
US Food and Drug Administration

Dr. Sean Khozin, MD, MPH, is a physician-data scientist who has been building solutions at the intersection of health care and technology for over a decade. A thoracic oncologist by training, Dr. Khozin currently serves as Associate Director of FDA's Oncology Center of Excellence, helping drive the new center's mission of achieving patient-centered regulatory decision making through innovation and collaboration. Dr. Khozin is Founding Director of Information Exchange and Data Transformation (INFORMED), FDA's first data science and technology incubator for collaborative regulatory science research focused on supporting cutting-edge initiatives that enhance the agency's mission of promotion and protection of public health.

Previously, Dr. Khozin owned and managed a multidisciplinary health care delivery network in New York City as a practicing physician and was a serial entrepreneur specializing in building health information technology systems with telemedicine, point-of-care data visualization, and advanced analytics capabilities.

Stephen Kindred, MD

Assistant Vice President and Medical Director
State Farm

Svetlana Kobina

Vice President of Global Medical Affairs
Bayer

Jennifer Kronick

Vice President, Human Resources and Law
Loxo Oncology

Before her current position at Loxo Oncology, Ms. Jennifer Kronick was Senior Assistant General Counsel at Purdue Pharma, where her work included an international assignment in Basel, Switzerland, supporting emerging markets. Ms. Kronick also worked as a labor and employment law associate at Morgan Lewis in New York and as a Trial Preparation Assistant in the New York County District Attorney's Office Sex Crimes Prosecution Unit.

Ms. Kronick received her BA degree with college honors from Washington University in St. Louis and her law degree from Columbia Law School, where she was a Harlan Fiske Stone Scholar. She is admitted to practice in Connecticut and New York.

Jo Lager, MD

Head of Oncology Development
Sanofi

Dr. Jo Lager has been in positions of increasing responsibility within Sanofi since joining in 2009 and has been the Head of Oncology Development since 2014. Prior to joining Sanofi, Dr. Lager worked at GlaxoSmithKline in Oncology Discovery Medicine and Clinical Pharmacology. She holds an MD from Duke University and trained at Duke University in pediatric hematology and oncology.

Kenneth B. Lee, Jr.

Chief Financial Officer, *CEO Roundtable on Cancer*
General Partner, Hatteras Venture Partners

Mr. Ken Lee is involved in deal sourcing, investment decisions and implementing exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Mr. Lee is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

Mr. Lee got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm's national life sciences practice, he advised numerous high-profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. These companies included Affymax, Affymetrix, Applied Immune Sciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA and Collagen.

Mr. Lee is a nationally recognized financial matters expert and serves on the boards of CV Therapeutics, Abgenix, OSI Pharmaceuticals, Pozen, Inspire Pharmaceuticals (ISPH), Maxygen (MAXY) and Clinverse. He is the Chairman of the Board of Clinipace and former Chairman of the Board of Inspire Pharmaceuticals Inc. (ISPH).

Melissa Lesley

Vice President of Total Rewards
Advance Auto Parts

Douglas R. Lowy, MD

Deputy Director
National Cancer Institute (NCI)

A cancer researcher for more than 40 years, Dr. Douglas Lowy has served as Deputy Director of the NCI since 2010. He received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine. As chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI, Dr. Lowy's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. His laboratory, in close collaboration with John T. Schiller, PhD, was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three US Food and Drug Administration-approved HPV vaccines.

Dr. Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. For their pioneering work, Dr. Lowy and Dr. Schiller have received numerous honors in addition to the National Medal, including the Federal Employee of the Year Award in 2007 from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2017 Lasker-DeBakey Clinical Medical Research Award.

Dr. Lowy received his medical degree from New York University School of Medicine, New York City, and trained in internal medicine at Stanford University, California, and dermatology at Yale University, New Haven, Connecticut.

Anne Lubenow

Deputy Executive Officer
National Cancer Institute

Katie W. Mahoney

Vice President of Health Policy
US Chamber of Commerce

Katie W. Mahoney rejoined the US Chamber of Commerce in June 2010. Mrs. Mahoney has 20 years of health care experience in hospital and health plan operations as well as health policy. She is responsible for developing, advocating and publicizing the Chamber's policy on health and works with members of Congress, the administration and regulatory agencies to promote the organization's health policy. Mrs. Mahoney also crafts regulatory responses for the Chamber and its member companies and addresses material areas as part of a comprehensive health policy.

Mrs. Mahoney joined the Chamber from the law firm of Greenberg Traurig where she served as assistant director of health and FDA business. There she analyzed legislative and regulatory health care proposals and advised insurers, health care providers and employers on the respective business impact.

Previously, Mrs. Mahoney worked at the US Chamber as director of health care policy from 2004 to 2007. She focused on access to health coverage for small businesses and the uninsured, health plan mandates, ERISA preemption and regulatory requirements, COBRA, Medicare payment systems, retiree health coverage, medical liability reform, and health care quality improvement initiatives.

Mrs. Mahoney has consulted on a variety of projects for state agencies and hospitals to maximize reimbursement and improve coverage among underserved populations, using public financing strategies. Her operational experience includes negotiating, implementing and monitoring all managed care agreements with hospitals and health systems, large medical groups and ancillaries in Southwest Central Louisiana on behalf of the largest single health carrier in the US. She completed a postgraduate fellowship with the then-fully integrated Ochsner Health System, working at the executive level with chief executive officers at the Ochsner Health Plan, the Ochsner Clinic and the Ochsner Foundation Hospital.

Originally from Massachusetts, Mrs. Mahoney graduated cum laude from Vanderbilt University with an undergraduate degree in English literature. She earned a law degree and a master's degree in health administration from Tulane University's School of Law and School of Public Health and Tropical Medicine, respectively.

François Maisonrouge

Senior Managing Director
Evercore Partners

Ameet Mallik

Executive Vice President, Head of US Oncology
Novartis

Angel Martin

Manager of Grants and Special Projects
Emerson Collective

Wendy McDermott
Vice President of Human Resources
Sanofi

Dan McHugh
Portfolio Manager for Health
Sanofi

David Miller
Clinical Associate
Massachusetts General Hospital

Ann Murphy, PhD
Publisher and Executive Editor
The Oncologist, STEM CELLS and STEM CELLS Translational Medicine



Dr. Ann Murphy has managed STEM CELLS, the oldest journal in the fast-paced area of stem cells and regenerative medicine, for 36 years. She maintains the journal's excellence as it exponentially expands its size and scope as a top-tier global peer-reviewed journal devoted to stem cell biology.

STEM CELLS Translational Medicine (SCTM), now in its seventh volume, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. As executive editor, Dr. Murphy works closely with founding editor-in-chief Anthony Atala.

Dr. Murphy is also one of the founding editors of The Oncologist, a monthly journal for physicians devoted to cancer patient care, and has guided and nurtured its growth and development over its 23-year history. She has also led The Oncologist Continuing Medical Education Program from its inception.

The Oncologist is the official journal of Society for Translational Oncology (STO). Dr. Murphy played a salient role when the senior editors of The Oncologist founded STO in 2000 to fill the gap between discovery of new oncology treatments and their global translation into oncology practice. The society is accredited by the ACCME, and Dr. Murphy serves as the society's Director General.

Dr. Murphy holds a PhD with distinction in literature from New York University. She serves on the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish literary renaissance and the biographer of the Irish playwright and poet Padraic Colum.

Martin J. Murphy, DMedSc, PhD, FASCO

Chief Executive Officer, Co-Founder, *CEO Roundtable on Cancer*



Dr. Martin Murphy is a member of the National Cancer Policy Forum of the National Academy of Medicine and the National Academy of Sciences; a Director of the Foundation for the National Institutes of Health. He is a Fellow of the American Society of Clinical Oncology, and founding Executive Editor of the peer-reviewed biomedical journal *The Oncologist*, *Stem Cells* and *Stem Cells Translational Medicine*.

A co-founder of the Society for Translational Oncology; a member of the Scientific Advisory Board of Hatteras Venture Partners; a charter member of the International Advisory Board of the VU University Medical Imaging Center; a charter member of Queen's University Belfast School of Medicine International Review Board; Dr. Murphy is also Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO); convener of ACT-China; and a steering committee member and senior consultant to the Chinese Society of Clinical Oncology.

Dr. Murphy is founding CEO of *Project Data Sphere®, LLC*, a non-profit enterprise devoted to cancer clinical trial data-transparency, data sharing and data analysis founded by the *CEO Roundtable on Cancer's* Life Sciences Consortium.

Sharyl Nass, PhD

Director, Board on Health Care Services
Director, National Cancer Policy Forum

Dr. Sharyl Nass serves as Director of the Board on Health Care Services and Director of the National Cancer Policy Forum at the National Academies of Sciences, Engineering and Medicine. The National Academies provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology and medicine. To enable the best possible care for all patients, the Board undertakes scholarly analysis of the organization, financing, effectiveness, workforce and delivery of health care, with emphasis on quality, cost and accessibility. The Cancer Forum examines policy issues pertaining to the entire continuum of cancer research and care.

For nearly two decades, Dr. Nass has worked on a broad range of health and science policy topics that includes the quality and safety of health care and clinical trials, developing technologies for precision medicine, and strategies for large-scale biomedical science. She has a PhD in cell biology from Georgetown University and undertook postdoctoral training at the Johns Hopkins University School of Medicine, as well as a research fellowship at the Max Planck Institute in Germany. She also holds a BS and an MS from the University of Wisconsin-Madison. She has been the recipient of the Cecil Medal for Excellence in Health Policy Research, a Distinguished Service Award from the National Academies, and the Institute of Medicine staff team achievement award (as team leader).

Daniel P. O'Day

Chief Executive Officer
Roche Pharmaceuticals

Mr. Daniel O'Day was appointed CEO of Roche Pharmaceuticals in September 2012. Previously, Mr. O'Day was the Chief Operating Officer of the Diagnostics Division, starting in January 2010.

Mr. O'Day acquired extensive commercial experience through diverse roles within Roche worldwide. These began at Roche Pharma in the US, where he held various commercial and sales roles between 1987 and 1998. Mr. O'Day then moved to the Roche Pharma headquarters in Switzerland, where he held leadership roles in Global Marketing and Lifecycle Management until 2001. Subsequently, he was Head of Corporate Planning at Roche Pharma in Tokyo between 2001 and 2003; General Manager at Roche Pharma in Denmark between 2003 and 2006; and President of Roche Molecular Diagnostics in California between 2006 and 2009.

Mr. O'Day obtained a Bachelor of Science degree in biology from Georgetown University in 1986 and an MBA from Columbia University in 1997.

Arthur Pappas

Managing Partner
Pappas Capital

Philip D. Porter, JD, MEd

Special Counsel, *CEO Roundtable on Cancer*
Senior Counsel, Hogan Lovells US LLP



Mr. Philip Porter cut his legal teeth on software license deals in the early 1980s, when most people had only a vague idea about computers and no clue about software. A few years later, he was negotiating ownership of inventions made during clinical trials at a time when contracts did not address ownership. Before the rest of us had heard of the World Wide Web, Mr. Porter was writing website development agreements and auditing client websites for compliance with rapidly developing laws.

Mr. Porter helps clients with commercial transactions involving technology and intellectual property. He has led a team that structured a technology outsourcing transaction valued at over $1 billion, helped an offshore university acquire one of the world's largest supercomputers and the skills needed to operate and maintain it, and orchestrated what was believed to be the first deal between a US pharmaceutical company and a Chinese research firm to co-develop compounds.

Since 2013, Mr. Porter has focused on providing pro bono assistance to a nonprofit that makes clinical trial data available for access by researchers worldwide. As part of a US government program, he has conducted training for lawyers and academics from third-world countries in structuring and negotiating technology transfer transactions. He also conducts continuing legal education programs and development classes.

Chandra Ramanathan, PhD, MBA

Vice President and Head of East Coast Innovation Center
Bayer

David M. Reese, MD

Co-Chair, *Life Sciences Consortium* Task Force
Executive Vice President, Research and Development
Amgen

In his role at Amgen, Dr. David M. Reese oversees discovery research, global development, global regulatory affairs and safety, as well as global medical. Dr. Reese joined Amgen in 2005 and has served in various leadership roles within the Research and Development organization. This includes most recently serving as Senior Vice President of Translational Sciences and Oncology, where he oversaw the translation of Amgen's medicines from the lab into the clinic and the overall oncology strategy.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization. Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in internal medicine and hematology/oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

Christine Roth

Senior Vice President and Head of Global Oncology
GSK

Mace L. Rothenberg, MD

Co-Chair, Life Sciences Consortium Task Force
Chief Development Officer for Oncology, Global Product Development Group
Pfizer

Dr. Mace Rothenberg is responsible for overseeing clinical research and development activities for all promising oncology products in Pfizer's Global Product Development Group. He is a member of the Global Product Development and Pfizer Oncology Leadership Teams and Pfizer's Senior Leadership Council. He also co-chairs the *Life Sciences Consortium* of the *CEO Roundtable on Cancer*, is a member of the National Cancer Policy Forum of the National Academy of Medicine, and serves on the NYU School of Medicine's Alumni Board of Governors.

Dr. Rothenberg came to Pfizer in 2008 after 25 years in academia where he focused on early-stage drug development, clinical trial design, and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers. While in academia, Dr. Rothenberg chaired the pivotal clinical trials that led to FDA approval of irinotecan (CPT-11, Camptosar®) and oxaliplatin (Eloxatin®) for colorectal cancer, and one of the key trials used as the basis for approval of gemcitabine (Gemzar®) for pancreatic cancer. At Pfizer, Dr. Rothenberg's organization has been responsible for the successful development and regulatory approval of seven new cancer drugs over a period of eight years: crizotinib (Xalkori®) for ALK+ and ROS1+ non-small cell lung cancer, axitinib (Inlyta®) for renal cell carcinoma, bosutinib (Bosulif®) for Ph+ chronic myelogenous leukemia, palbociclib (Ibrance®) for ER+ advanced breast cancer (Prix Galien Award winner in 2016 for Best Pharmaceutical Product), avelumab (Bavencio®) for Merkel cell and urothelial carcinomas, inotuzumab ozogamicin (Besponsa®) for acute lymphocytic leukemia, and gemtuzumab ozogamicin (Mylotarg®) for acute myelogenous leukemia.

Dr. Rothenberg is the recipient of the American Cancer Society's Lane W. Adams Quality of Life Award and the American Society of Clinical Oncology's Statesman Award. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Dr. Rothenberg received his BA from the University of Pennsylvania, his MD from the New York University School of Medicine, his post-graduate training in internal medicine at Vanderbilt University and his medical oncology training at the National Cancer Institute. He also served on the faculties of the University of Texas Health Science Center – San Antonio and Vanderbilt University.

Björn Rüter

Executive Director and Therapeutic Area Head, Oncology
Boehringer Ingelheim

Charles A. Sanders, MD

Chairman Emeritus, Foundation for the National Institute of Health (FNIH)
Retired Chairman and Chief Executive Officer, Glaxo

Peter Sandor, MD, MBA

Vice President of Global Therapeutic Area Head Oncology
Astellas

Chris Sarchi

North American Head of Oncology and Transplant
Sanofi Genzyme

Mr. Chris Sarchi is responsible for all aspects of marketing and commercialization of oncology and transplant products at Sanofi Genzyme for North America.

Mr. Sarchi joined Sanofi Genzyme in December 2017, following a successful career in the pharmaceutical and biotechnology industry spanning over 25 years. During this time, he held various leadership positions in sales, marketing, strategic planning and new product development, as well as business unit leadership covering multiple therapeutic areas.

Prior to his current role, Mr. Sarchi was the Vice President and BU Head of Oncology and Biosimilars at Boehringer Ingelheim from 2013 to 2018. At BI, he was responsible for the initial build out of the oncology field commercial team. Mr. Sarchi has had additional leadership opportunities and experiences during his time at GSK, as well as Roche/Genentech

Jay J. Schnitzer, MD, PhD

Vice President and Chief Technology Officer
The MITRE Corporation

Dr. Jay Schnitzer is Vice President and Chief Technology Officer at The MITRE Corporation. He oversees MITRE's internal research and development program and corporate technology transfer efforts. In this role he helps the organization ensure a world-class internal R&D effort that supports the entire corporation; deliver transformational capabilities that drive mission success; meet the needs of the direct work programs and federal sponsors through innovation and transitional technology directly to government; and return value to the nation by transferring innovations to industry.

Previously, Dr. Schnitzer was the Director of Biomedical Sciences at MITRE, managing the organization's health transformation research and development program. In this role, he identified opportunities for MITRE to make transformative difference in healthcare and provided expert clinical and medical input on health-related projects. Recently, he led the writing and editing of the Integrated Report for the Independent Assessment performed in response to Section 201 of Veterans Choice Act, and organized and facilitated the Blue Ribbon Panel.

Before joining MITRE, Dr. Schnitzer was the Director of the Defense Sciences Office at the Defense Advanced Research Projects Agency (DARPA). In this role, he led a team of 20 program managers and 70 support staff overseeing research and development across multiple domains, from life sciences and biomedical research to quantum physics. Before DARPA, Dr. Schnitzer was at Boston Scientific Corporation as Chief Medical Officer and Senior Vice President, where he provided medical and clinical oversight for all medical devices manufactured by the endoscopy, urology/women's health, neurovascular and neuromodulation divisions of the company.

Dr. Schnitzer has also held a staff appointment at Massachusetts General Hospital as an attending pediatric surgeon, with a joint appointment at Shriners Burns Hospital, and was a faculty member at Harvard Medical School. He was also the surgical team leader for the National Disaster Medical System (NDMS) International Medical Surgical Response Team (east) (IMSuRT-E).

He received a BS in chemical engineering from Worcester Polytechnic Institute, a PhD in chemical engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Dr. Schnitzer completed his residency training program in general surgery at the Brigham and Women's Hospital, Boston, and a fellowship in pediatric surgery at Children's Hospital, Boston.

Robert J. Schotzinger, MD, PhD

President and CEO
Selenity Therapeutics

Dr. Robert Schotzinger brings more than 20 years of research, development, financing and management expertise to Selenity Therapeutics, a company formed from Viamet Pharmaceuticals following the sale of Viamet's clinical stage antifungal portfolio to NovaQuest Capital Management in 2018. Prior to Selenity, Dr. Schotzinger was co-founder and CEO of Viamet Pharmaceuticals, where he raised significant equity capital and moved the organization from a seed-stage company to a successful clinical-stage company. Prior to joining Viamet Pharmaceuticals, Dr. Schotzinger was President and CEO of BioStratum, where he was responsible for progressing the company's lead drug candidate from phase 1 to phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his BS in pharmacy from The Ohio State University. He subsequently earned his PhD degree in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to board certification in internal medicine.

Michael Severino, MD

Executive Vice President, Chief Scientific Officer
AbbVie

Dr. Mike Severino leads the discovery, research and development of AbbVie therapies, and is responsible for managing scientific partnerships and establishing research and development strategies for the company.

Prior to joining AbbVie, Dr. Severino was Senior Vice President and Chief Medical Officer at Amgen, Inc. While at Amgen, he served in several leadership positions and supervised broad therapeutic areas including oncology, inflammation, neuroscience and metabolic disorders.

He earned a bachelor's degree in biochemistry from the University of Maryland, College Park, and a doctorate in medicine from the Johns Hopkins University in Baltimore. Dr. Severino completed research and post-doctoral training at Massachusetts General Hospital and Harvard Medical School in Boston, completing his residency in internal medicine.

Norman E. Sharpless, MD

Director
National Cancer Institute

Dr. Ned Sharpless was officially sworn in as the 15th director of the National Cancer Institute (NCI) on Oct. 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, a position he held since January 2014.

Dr. Sharpless was a Morehead Scholar at UNC-Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston.

After two years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians as well as the American Society for Clinical Investigation (ASCI), the nation's oldest honor society for physician-scientists, and served on the ASCI council from 2011 to 2014. Dr. Sharpless was an associate editor of Aging Cell and deputy editor of the Journal of Clinical Investigation. He has authored more than 150 original scientific papers, reviews and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics.

In addition to serving as Director of NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer and breast cancer.

David Shepperly, MD, MHS, FACOEM

Head of Employee Health and Fitness
Bristol-Myers Squibb

Dr. David Shepperly is the Global Leader for Employee Health and Fitness at the Bristol-Myers Squibb Corporation. Bristol-Myers Squibb is a diversified specialty biopharma company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. In this role, Dr. Shepperly is responsible for developing and managing the employee health and fitness strategy for Bristol-Myers Squibb, including the occupational health services and implementation of the global well-being strategy.

Prior to joining Bristol-Myers Squibb, Dr. Shepperly held a variety of medical director positions at ExxonMobil and was the Corporate Medical Director for the Solutia Corporation. Dr. Shepperly received his Bachelor of Arts degree in biology from Colorado College. He is a graduate of the University of Colorado Health Sciences Center where he received his Doctorate of Medicine. He has a Master of Health Sciences in biostatistics from the Johns Hopkins School of Hygiene and Public Health. Dr. Shepperly completed his residency in internal medicine and occupational medicine at Morristown Memorial Hospital/Columbia University. Dr. Shepperly is board certified in occupational medicine and is a Fellow of the American College of Occupational and Environmental Medicine.

Ann Skye

Associate Director for Employee Health Management
IQVIA

Ms. Ann Skye is responsible for the strategy, design and implementation of her company's comprehensive and robust well-being program and initiatives across the globe, serving over 36,000 employees. Her current focus is on post-merger integrations, including global tobacco-free workplace, employee assistance program and resilience/energy management initiatives to assist others through continual change. Ms. Skye serves on the boards of local Girls on the Run and YMCA organizations and strives to have a positive impact whether close to home or oceans away.

Ms. Skye received her MPH from The University of North Carolina and her BSN from The University of Michigan. She has been involved in the *CEO Cancer Gold Standard* program from the beginning as a successful company applicant in the first wave of accreditations in 2006, an attendee at the 2007 *CEO Roundtable on Cancer* meeting in NYC, and on the task force and accreditation review board since that time. She is excited to lead the Global *CEO Gold Standard* subcommittee as it assists companies in extending their *Gold Standard* impact worldwide.

Tania Small

Vice President and Head of Medical Oncology Franchise
GSK

Jeffrey Spaeder, MD

Chief Medical and Scientific Officer
IQVIA

As the lead medical and scientific expert at IQVIA, Dr. Jeffrey Spaeder is involved with the company's oversight of scientific integrity, governance of early phase development, quality assurance and bioethics.

Dr. Spaeder has nearly 25 years of medical and research experience, and since 2005 has worked in the life sciences industry. Prior to joining IQVIA, he worked in roles of increasing responsibility at Abbott Laboratories and Takeda in clinical development, pharmacovigilance and medical affairs. He also was a cardiologist on the faculty of Johns Hopkins School of Medicine, where he performed novel research on mass customization of personalized health care and telemedicine, and he holds several patents based on his research and insights.

Dr. Spaeder holds a MD from Johns Hopkins School of Medicine and completed specialty training in internal medicine at Johns Hopkins and sub-specialty training in cardiovascular medicine from Johns Hopkins and the National Heart, Lung, and Blood Institute. He holds an undergraduate degree in engineering science from the Pennsylvania State University and a master's in business administration with a concentration in finance from Northwestern University's Kellogg School of Management.

Richard Staub

President, Research and Development Solutions
IQVIA

Mr. Richard Staub is president of the Research & Development Solutions global business unit at IQVIA, leading the world's largest contract research organization (CRO). Supported by high-powered information and technology assets, the clinical experts in Research & Development Solutions leverage comprehensive, evidence-driven trial design, accelerate site activation and patient recruitment, and optimize trial execution. Mr. Staub also serves as chair of the Research & Development Solutions Executive Committee.

Previously, he led Novella Clinical, a specialty clinical research organization acquired by Quintiles in 2013. Mr. Staub joined Novella in 2004 and served as both president and CEO. Under his leadership, Novella became a distinctively agile, results-oriented CRO in the highly complex and fast-growing areas of specialty pharma and medical technology. Prior to Novella, he was senior vice president of global business development for one of the world's largest CROs. Mr. Staub's career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he was given increasing responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager.

Mr. Staub has a bachelor's degree in economics from the University of North Carolina at Chapel Hill.

Gail Stephens

Vice President of Research and Development
SAS

Zhen Su, MD

Senior Vice President and Chief Medical Officer
EMD Serono, North America

In his role at EMD Serono, Dr. Zhen Su leads medical strategy for all products in North America and drives execution of medical initiatives focusing on improving patient outcomes in key therapeutic areas, including neurology, immunology, oncology, fertility and endocrinology. A physician executive with nearly 20 years of experience, Dr. Su has strong clinical expertise in oncology, urology and immuno-oncology.

Dr. Su joined EMD Serono in 2015 as Vice President and Head of US Medical Affairs for Oncology, and successfully built an oncology medical affairs team from the ground up. The team supported the global launch of BAVENCIO and the co-promotion of XALKORI in the US and Canada through the strategic alliance between EMD Serono, the North America Healthcare Business of Merck KGaA, Darmstadt, Germany and Pfizer. More recently, Dr. Su was appointed as Global Head of Medical Affairs Oncology, leading medical affairs activities to support the market leadership of ERBITUX (outside the US and Canada), global BAVENCIO launches and acceleration of the oncology pipeline.

Dr. Su has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, he served as Associate Vice President and Global Head of Jevtana® (cabazitaxel) at Sanofi and Country Medical Director for GSK Canada. Dr. Su previously held several academic positions, including Assistant Professor of Surgery at Duke University Medical Center, where he also received his postdoc fellowship in genitourinary oncology. He then served as Assistant Professor and Cancer Immunotherapy Program Director at the University of Florida.

Dr. Su has deep ties to the oncology community, having worked with leading oncologists at organizations globally. He earned his MD degree from the Technical University of Dresden, Germany, and completed his MBA training at the University of Toronto.

Craig L. Tendler, MD

Vice President, Oncology Clinical Development and Global Medical Affairs
Janssen

Dr. Craig Tendler is responsible for creating robust development plans and data generation activities for all products in the Janssen Oncology portfolio, from late development through registration and lifecycle management, that support regulatory approval and provide access for the benefit of patients. He works closely with early development and the disease area strongholds to implement a seamless end-to-end oncology clinical research strategy that incorporates compelling science and addresses areas of high unmet medical need.

Dr. Tendler has overseen and coordinated 26 major drug approvals by national regulatory agencies, including 12 by the US Food and Drug Administration (FDA). Most recently his team worked in collaboration with FDA and EMA to secure the expeditious worldwide approval of IMBRUVICA for relapsed mantle cell lymphoma, Waldenstrom's Macroglobulinemia and CLL as well as ZYTIGA® for the treatment of metastatic castration resistant prostate cancer and DARZALEX for refractory multiple myeloma.

Dr. Tendler and his team have played a key role in achieving several FDA Breakthrough Designations for ibrutinib and daratumumab, in collaboration with co-development partners Pharmacyclics and Genmab, respectively.

In addition to his pharmaceutical industry experience, Dr. Tendler has served as Assistant Professor of Pediatrics at the Mount Sinai School of Medicine in New York City and was a research fellow and recipient of a Physician Scientist Training Award at the National Cancer Institute.

Dr. Tendler earned his undergraduate degree from Cornell University and graduated from the Mount Sinai School of Medicine with high honors (AOA). He is board certified in Pediatrics with a subspecialty in Hematology-Oncology.

Clay Thorp

General Partner
Hatteras Ventures

Mr. Clay Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena. Since co-founding Hatteras in 2000, Mr. Thorp has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. He has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics and research informatics.

Mr. Thorp began his career in 1995 when he co-founded Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Shortly thereafter, he co-founded Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon's sale to Karo Bio for $106.7 million in May 2000. Subsequently, he applied his entrepreneurial passions to co-founding Hatteras Venture Partners (formerly Catalysta Ventures). Since that time, Hatteras has invested in over 60 companies in the life science industry, serving as the founding or first institutional investor in over half of these. Mr. Thorp has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical, Lysosomal Therapeutics, Asthmatx, PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix. At Synthematix, he served as CEO and Chairman from inception in 2000 until the company was acquired in April 2005 by Symyx Technologies.

Mr. Thorp currently serves as Executive Chairman of PhaseBio Pharmaceuticals and Chairman of GeneCentric Diagnostics. He is also on the boards of Clearside Biomedical (Nasdaq: CLSD), Rodin Therapeutics, Lysosomal Therapeutics, Artizan Biosciences and Orig3n. He serves on the Chancellor's Philanthropic Committee at UNC-Chapel Hill, the Board of Visitors of the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill, and on the board of the NC School of Science and Mathematics Foundation.

Mr. Thorp started his career as a social entrepreneur by co-founding the Student Coalition for Action in Literacy Education (SCALE) as a junior at UNC-Chapel Hill in 1989. For that, he was honored as Point of Light by President George H.W. Bush. Since that time, Clay has been active at state and national levels in public policy and public service. He is a past board member of the NC Biotechnology Center, CED, Public Allies and the Wildacres Leadership Initiative. He holds a Master in Public Policy from Harvard University and a BA in mathematics and art history from the University of North Carolina at Chapel Hill.

Ann Morgan Vickery, JD

Senior Counsel
Special Counsel, *CEO Roundtable on Cancer*

Ms. Ann Vickery uses her health care policy expertise to help manufacturers, associations and providers of various health care products and services to understand the effect of federal laws, regulations and policies on their businesses, with a particular emphasis on Medicare and Medicaid.

Over the years, Ms. Vickery has worked to reform the US health care system, including involvement in the enactment of the Medicare hospice benefit in 1982. She continues to have a special interest in end-of-life care.

Before retiring from the partnership at the end of 2012, Ms. Vickery was active in the Hogan Lovells health practice, which she led as practice director from 1991 to 2010. Today, she is of Counsel in the firm's Washington, DC, office. She has also been active in the firm's management, serving two three-year terms on the Executive Committee of Hogan and Hartson (now Hogan Lovells) and as Managing Partner of its Washington, DC, office.

Before joining Hogan Lovells, Ms. Vickery served for a number of years in the executive branch of the federal government. From 1975 to 1978, she worked on the staff of the US Secretary of the Treasury, and from 1969 to 1974, she was a researcher and staff assistant on the White House staff.

Christopher A. Viehbacher

Immediate Past Chairman, *CEO Roundtable on Cancer*
Managing Partner, Gurnet Point Capital

Mr. Christopher Viehbacher is the Managing Partner of Gurnet Point Capital, a Boston-based investment fund associated with the Bertarelli family with a $2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc; the Chairman of Vedanta, a Pure Tech portfolio company; and a member of the Board of Trustees of Northeastern University.

Mr. Viehbacher is the former CEO and member of the board of directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.

Prior to joining Sanofi, Mr. Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a member of the board of directors of GSK plc in London and Co-President of GSK's Portfolio Management Board. He began his career with Price Waterhouse after graduating with a degree in Commerce at Queen's University in Canada.

Mr. Viehbacher has been a strong advocate for the health care industry. Current and past advocacy roles include:

Former Co-chair with Bill Gates for the CEO Roundtable on Neglected Diseases, Immediate Past Chairman of the CEO Roundtable on Cancer, Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington, and President of the European Federation of Pharmaceutical Industries and Associations in Brussels. He is Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living and Member of the International Business Council.

Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen's University at Kingston, Ontario. He has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide, and France's highest civilian honor, the Legion d'Honneur.

Karen J. Walters

Co-Chair, *CEO Cancer Gold Standard* Task Force
Clinical Service Support Director, Independence Blue Cross

Ms. Karen Walters supports special projects and key strategic initiatives for the Chief Medical Officer at Independence Blue Cross, the leading health insurance organization in southeastern Pennsylvania. With its affiliates, the company serves more than 8 million people nationwide. Prior to this position, she served as the Director of Associate Wellness and Communications, where she developed the annual wellness operating plan for the company's more than 4,400 associates and oversaw all internal and external wellness communications.

Before her tenure in the health insurance industry, Ms. Walters held a variety of roles in the financial services and investment management industry. She has extensive experience in strategic marketing and communications, and start-up departmental ventures.

Ms. Walters has a master's degree in wellness and lifestyle management from Rowan University, an MBA in finance from New York University, a bachelor's degree from Villanova University in business administration with a marketing concentration, and an associate's degree from Parsons School of Design.

Kai Wang, MD, PhD

Founder and CEO
OrigiMed

Mr. Kai Wang in 2016 founded OrigiMed, a medical science and technology company focused on developing new technologies and clinical applications for cancer patients.

Prior to founding OrigiMed, Mr. Wang worked at Foundation Medicine in product development, clinical annotation, molecular pathology, medical consultancy and supporting NIH developing cancer sequencing standards.

Mr. Wang has been focused on next-generation sequencing cancer research since 2007. From 2001 to 2003, he worked on Sanger sequencing projects at BGI. He has more than 70 publications and 15 scientific journal reviews and has developed several bioinformatics software and NGS pipelines.

Mr. Wang holds a PhD in bioinformatics from the Center for Biological Sequence Analysis through the Denmark center's exchange program with UCLA. He also holds an MD from Norman Bethune Medical School in China and was a postdoctoral research fellow at the Dana-Farber Cancer Institute through Harvard Medical School.

Catharine Young, PhD

Senior Director of Science Policy
Biden Cancer Initiative



Originally from South Africa, Dr. Catharine Young holds a doctorate degree in biomedical sciences and currently serves as the Senior Director of Science Policy for the Biden Cancer Initiative. Here her portfolio covers all things science, data and tech as related to ending cancer as we know it. Prior to this position, Dr. Young served as the Senior Science and Innovation Policy Advisor and Head of the DC team for the Foreign Ministry of the UK. Based at the British Embassy, Dr. Young influenced science and innovation policies of the UK and US governments, industry and academia. Following her postdoctoral training at Cornell University in biomedical engineering, Dr. Young was selected as a AAAS Science and Technology Policy Fellow in the Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs. Here she led international engagements on eliminating biological weapons, improving biosafety and biosecurity, and assisted with the DoD's response to the Ebola outbreak in Western Africa. She also co-founded Blueprint International, a nonprofit dedicated to providing novel technological solutions to some of the world's most pressing social issues.

Recent awards include being selected as a TED Fellow, Alexandria 40 Under 40 and Social Enablers top 100 most inspiring social entrepreneurs. Dr. Young is an advocate for women in STEM and has been a contributor to major social and media networks including TED-Ed, the Guardian and the UK Science and Innovation Network.

Névine Zariffa

Vice President and Head of Biometrics and Information Sciences
AstraZeneca

Ms. Névine Zariffa was born in Cairo and raised in Montréal. After her training at McGill University and at the University of Waterloo (mathematics and statistics), she began her career as a statistician supporting agricultural research before moving to Philadelphia to join SmithKline Beecham in 1991, which went on to become GlaxoSmithKline. She joined AstraZeneca in November 2011 and is currently VP and Head of Biometrics and Information Sciences in Global Medicine Development. In 2018, Ms. Zariffa took on leadership of the enterprise data and analytics program at AstraZeneca, which will lay a companywide IT and governance infrastructure for data, enhance acumen in data sciences to generate insights, and engage with the full employee base to evolve culture to use these insights in decision making.

Over the last 25 years, Ms. Zariffa has amassed a wealth of experience in her specialist area and also in driving strategic programs. She has supported early and late-stage clinical development and marketed products – primarily in the area of cardiovascular and metabolism – and has led global teams of quantitative experts across many quantitative disciplines. Ms. Zariffa has also led, or played an integral part in, numerous strategic initiatives, working with company colleagues, medical associations, academics and other groups (both PhRMA and FDA-sponsored) to enhance the value of quantitative sciences beyond the traditional role of designing, analyzing and interpreting clinical trials. Ms. Zariffa has been a statistical reviewer for The Lancet and is the author or co-author of over 25 publications in peer reviewed biostatistics and medical journals.

Gary Zieziula

Senior Advisor
EMD Serono

Helmut Zodl

Senior Vice President, Finance
Advance Auto Parts

Mr. Helmut Zodl joined Advance Auto Parts in 2017 as Senior Vice President of Finance. He is responsible for a variety of finance disciplines for the company as well as its operational and performance management systems.

Prior to joining Advance, Mr. Zodl worked for Lenovo/IBM, where he most recently served as Chief Financial Officer of Lenovo's Global Services Business. During his nearly two decades with Lenovo/IBM, Mr. Zodl held various leadership roles in finance, including CFO positions in Asia Pacific, the Americas group, and global enterprise groups.

In addition to his finance leadership roles, Mr. Zodl has led several global, cross-functional activities and groups, including corporate strategy and mergers and acquisitions.

Mr. Zodl earned bachelor's and master's degrees from the Technical University of Vienna and an MBA from the University of Vienna.

CEO Roundtable on Cancer Staff

Lisa Austin

Program Manager
Project Data Sphere, LLC

In her role with *Project Data Sphere*, Ms. Lisa Austin focuses her efforts primarily on managing the efforts of the Imaging and Algorithms Task Force, including the upcoming Imaging and Algorithms Crowdsource Challenge. She recently moved to Durham, NC, from Arlington, VA, where she lived for nine years. There, she worked in health care consulting at Grant Thornton LLP, most recently for a major Department of Defense contract related to health care policy in the military health system. Prior to that, she worked at Verité Healthcare Consulting providing consulting services to not-for-profit health care systems and served as an administrator at the Capital Region Children's Center, a practice that provides mental health care to at-risk children in the Washington, DC, metropolitan area. She has her Master of Business Administration and Master of Health Care Administration from the University of Alabama at Birmingham and a Bachelor of Science from Davidson College. She is also a certified Project Management Professional.

John Bluth

Strategic Communications Leader
CEO Roundtable on Cancer

Megan R. Granda, PhD

Project Manager
Project Data Sphere, LLC

Dr. Megan Granda, PhD, joined *Project Data Sphere, LLC* in August 2017 to help develop and manage the organization's research programs. Previously, she worked for more than 20 years in academic research at the University of Texas, Austin; University of North Carolina, Chapel Hill; and Duke University. Prior to *Project Data Sphere*, Dr. Granda managed a clinical research group under the direction of Dr. John Buse as part of the National Patient-Centered Clinical Research Network (PCORnet). She served as the executive director of the Office for Faculty Mentoring in Duke's School of Medicine and organized mentoring programs for junior faculty applying for NIH K-series and R-series grants. Her own research is in the humanities, and she spent the first part of her career directing UNC's Institute for the Arts and Humanities and Duke's Center for Civic Engagement. Dr. Granda is certified in project management through Duke University, biomedical research team mentoring through the National Research Mentoring Network, and in organizational leadership through the Center for Creative Leadership. She has worked extensively with academic faculty of all ranks in the schools of arts and sciences, law, public policy, business, medicine and nursing to enable and enhance institutional leadership, professional development and research output.

David Handelsman

Program Manager
Project Data Sphere, LLC

Mr. David Handelsman joined *Project Data Sphere, LLC* in July 2016, and has served in multiple capacities within the organization since that time. In his current role, Mr. Handelsman is responsible for the strategic growth of the *Project Data Sphere* platform in terms of patient lives, researcher value and technological capabilities, and is serving as the Program Manager for the Small Cell Lung Cancer External Control Arm research program. Mr. Handelsman was formerly responsible for strategic growth and product development at d-Wise, a high-tech company focused on developing software and delivering services to the health care industries. He played a key role in leading the development and marketing of d-Wise's patient data anonymization software application. Prior to joining d-Wise, Mr. Handelsman held a variety of leadership roles at SAS, where he served as the leading expert in clinical research and related health care fields and was instrumental in the success of the organization's clinical trial data sharing initiative. Mr. Handelsman also led data management, programming and biostatistics teams within the CRO industry, and recently completed his term as the Chair of the CDISC Advisory Council.

Mr. Handelsman received a BS in computer science and completed graduate studies in biomedical engineering from the University of Virginia.

Eileen Indorato

Executive Assistant
CEO Roundtable on Cancer

Bill Louv

President
Project Data Sphere, LLC

Dr. Bill Louv joined *Project Data Sphere, LLC* in March 2018 as President after holding key leadership positions in the pharmaceutical industry for nearly 30 years. He joined the pharmaceutical industry in 1986 as head of biostatistics at Merrell Dow and advanced to the position of Vice President of biostatistics, epidemiology and clinical data management at GlaxoWellcome in 1998. Dr. Louv made a significant career change in 1999 when he became Vice President of IT for GlaxoSmithKline's R&D organization. Dr. Louv was named Chief Information Officer for GSK in 2007. In 2011, he was promoted to Senior Vice President of Core Business Services which included IT, procurement, accounting and real estate. Dr. Louv was a member of GSK's Corporate Executive Management team from 2007 until his retirement in May 2016.

Dr. Louv has consulted with many organizations on health care analytics and opportunities to leverage big data. He is a Non-Executive Director of River Logic Inc., a leader in prescriptive analytics and integrated business planning, and he is Deputy Chairman of ClinPal, a cloud-based clinical trial platform.

In his early career, Dr. Louv was a technical staff member at Bell Laboratories where he developed forecasting algorithms for signaling networks. Subsequently, he was Associate Professor of Biostatistics at the University of Alabama at Birmingham. Dr. Louv published more than 25 academic papers while at these research organizations.

Nicole Hayes

Executive Associate
CEO Roundtable on Cancer
Project Data Sphere, LLC

Ms. Nicole Hayes is the Executive Associate for the *CEO Roundtable on Cancer* and *Project Data Sphere*. Her responsibilities include human resource and accounting support, assistance in planning and preparation of the annual meetings, board of directors meetings and symposia, along with maintaining database information, assisting with communication efforts and providing support to the staff and members of the *CEO Roundtable on Cancer*.

Prior to joining the *CEO Roundtable* in September 2016, Ms. Hayes worked 13 years for Robert A. Ingram, the Past Chairman and Co-Founder of the *CEO Roundtable on Cancer* and General Partner at Hatteras Venture Partners. She began her career in the human resource and recruiting fields on-site at GlaxoSmithKline and is a graduate of East Carolina University.

Becky Keith

Executive Coordinator
CEO Roundtable on Cancer

Ms. Becky Keith is the Executive Coordinator supporting Dr. Martin J. Murphy in his role as Chief Executive Officer of the *CEO Roundtable on Cancer*. In addition to administrative support, Ms. Keith's responsibilities include coordination of global travel arrangements, meeting planning, event scheduling and interacting with CEOs, government officials and international contacts. She maintains the HR records for the *CEO Roundtable on Cancer* and for the *CEO Roundtable on Cancer-China*. Ms. Keith also assists with communications and provides support to the staff and members of the *CEO Roundtable on Cancer* as needed.

Prior to beginning her employment with Dr. Murphy in August 2009, Ms. Keith worked with GlaxoSmithKline for 23 years in various departments throughout the RTP campus. Her last assignment was in the Robert A. Ingram Sales Training Center, where she supported the training efforts of the newly hired sales representatives.

Michael Litzsinger

Data Quality Expert
Project Data Sphere, LLC

Mr. Michael Litzsinger joined *Project Data Sphere, LLC*, in October 2018. He brings 30 years of statistical programming, hands-on management and technical leadership experience on both the sponsor and CRO sides of pharma.

Mr. Litzsinger maintains and optimizes the technical aspects of the data, standards and tools on the *Project Data Sphere* library-laboratory platform. He is passionate about clinical data acquisition and reporting, building practical metadata and tools that organize and analyze data for efficient clinical data research.

Mr. Litzsinger was formerly responsible for developing solutions and providing services for clinical data science and analysis, safety reporting and physician review at UCB Pharma. He implemented agile technical methodologies for reporting macros at Quintiles and then for analysis reporting at Schwarz Pharma while building an in-house statistical programming department. After starting as statistical programmer, he progressed into CRO and IT project management, then associate director and director responsibilities at Quintiles, Schwarz Pharma, UCB Pharma and PRA Health Sciences.

In his early career, Mr. Litzsinger engaged in clinical data research at the University of North Carolina, first as a student and then post-graduation at the Collaborative Studies Coordinating Center. Mr. Litzsinger also earned an MS in technology management from North Carolina State University.

Therese Martin

Program Manager
CEO Cancer Gold Standard™

Ms. Therese Martin serves as the Program Manager for the *CEO Cancer Gold Standard™*, a workplace accreditation program that encourages and recognizes the commitment of organizations that take concrete actions to address cancer in their workplaces. The *Gold Standard* is an initiative of the *CEO Roundtable on Cancer*, a nonprofit organization comprised of CEOs dedicated to eliminating cancer as a public health threat. Responsibilities include providing assistance to employers interested in adopting *Gold Standard*, conducting initial reviews of *Gold Standard* accreditation applications, serving as the primary interface with *Gold Standard* Task Force Members, and conducting outreach efforts to educate employers and promote the *Gold Standard*. Ms. Martin also manages program data and provides general support to *CEO Roundtable on Cancer* initiatives.

Prior to joining the *CEO Roundtable* in 2011, Ms. Martin worked as a program manager in a wide range of industries, including the military, software development, retail and nonprofit sectors. She is a graduate of the United States Air Force Academy, and earned her MBA in contracts and acquisition from Western New England College.

Sara Schweiger

Communications Specialist
Project Data Sphere, LLC

Laurie L. Stockton

Program Manager
Project Data Sphere, LLC

Ms. Laurie L. Stockton is the Program Manager for our immune-related adverse events (irAE) portfolio of data-driven projects and supports data quality initiatives for the PDS platform. After spending more than a decade collaborating with diverse teams at home and abroad, Ms. Stockton knows that the solutions to our most critical health problems depend on good, clean data. She believes the key to a strong data set is the ability to inspire a team effort. Her most recent work managing an NIH-funded study to increase adolescent HPV vaccination was preceded by data management activities for family planning and reproductive health studies in Africa and coordination of a randomized control trial of a program to promote adolescent tobacco cessation. She holds an MPH in maternal and child health with a minor in epidemiology from the Gillings School of Public Health at the University of North Carolina at Chapel Hill. Ms. Stockton enjoys reading, writing, snowboarding and rescuing Great Danes. She is an active Board Member for the Chatham County Youth Partnership and she serves as a Guardian ad Litem in Chatham County.

Betty M. Whichard

Director of Finance
CEO Roundtable on Cancer and *Project Data Sphere, LLC*

Prior to her time with *CEO Roundtable on Cancer*, Ms. Betty Whichard worked at The Medical Foundation of North Carolina as Vice President of Finance and Administration managing assets totaling approximately $315 million, and she served as the Financial Manager of Foundations and Alumni Association at East Carolina University. Ms. Whichard spent nine years as Chief Financial Officer, ERM and Operations Manager for 102 store locations for Trade Oil Company. In 2005, Trade Oil Company merged with WilcoHess, where she served as the Director of Finance and ERM. Ms. Whichard also served as the General Financial and Administrative Manager for the Greenville, NC divisional office, and spent 17 years in public accounting serving a diverse clientele.

Ms. Whichard is a member of the American Institute of CPAs and the North Carolina Association of CPAs. She is a graduate of the East Carolina University Chancellor's Leadership Academy and a graduate of Duke University Nonprofit Leadership Intensive Track Management Program. She holds a BSBA in accounting from East Carolina University and is a Certified Public Accountant.